Published in BMC Cancer on December 17, 2012
[Not Available]. MMW Fortschr Med (2013) 0.75
Chinese Herbal Medicine as Adjunctive Therapy to Chemotherapy for Breast Cancer: A Systematic Review and Meta-Analysis. Evid Based Complement Alternat Med (2016) 0.75
Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA (1998) 35.46
Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol (2010) 5.96
American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol (2006) 4.97
Use of complementary and alternative medicine in cancer patients: a European survey. Ann Oncol (2005) 3.98
A critical overview of homeopathy. Ann Intern Med (2003) 3.92
Homeopathic medicines for adverse effects of cancer treatments. Cochrane Database Syst Rev (2009) 2.58
On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol (1996) 2.03
'Alternative cancer cures': looking for common ground. Lancet Oncol (2000) 1.95
Patients' estimation of overall treatment burden: why not ask the obvious? J Clin Oncol (2002) 1.93
Update and new trends in antiemetic therapy: the continuing need for novel therapies. Ann Oncol (2010) 1.79
Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--an update. Support Care Cancer (2004) 1.56
Assessing the impact of chemotherapy-induced nausea and vomiting on patients' daily lives: a modified version of the Functional Living Index-Emesis (FLIE) with 5-day recall. Support Care Cancer (2003) 1.36
Chemotherapy-induced nausea and vomiting in routine practice: a European perspective. Support Care Cancer (2004) 1.30
Measuring the maintenance of daily life activities using the functional living index-emesis (FLIE) in patients receiving moderately emetogenic chemotherapy. J Support Oncol (2006) 1.28
Trends in breast cancer incidence, survival, and mortality. Lancet (2000) 1.27
Chemotherapy-induced nausea and vomiting. Cancer J (2008) 1.25
Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy. Support Care Cancer (2004) 1.13
Expectations of chemotherapy-related nausea: emotional and experiential predictors. Ann Behav Med (2003) 1.05
Use of alternative/complementary therapy in breast cancer patients--a psychological perspective. Support Care Cancer (2001) 1.01
Classical homeopathy in the treatment of cancer patients--a prospective observational study of two independent cohorts. BMC Cancer (2011) 0.94
Treatment of nausea and emesis during cancer chemotherapy. Discrepancies between antiemetic effect and well-being. J Pain Symptom Manage (2002) 0.94
The impact of postchemotherapy nausea and vomiting on quality of life after moderately emetogenic chemotherapy. Support Care Cancer (1998) 0.87
Homeopathy in cancer care. Altern Ther Health Med (2010) 0.85
[Breast cancer prevention behaviour: a perspective of women from three language regions of Switzerland]. Pflege (2004) 0.81
The homeopathic approach to symptom control in the cancer patient: a prospective observational study. Palliat Med (2002) 0.80
Controlling emesis in patients receiving cancer chemotherapy. Recent Results Cancer Res (1988) 0.80
International network of cancer genome projects. Nature (2010) 20.35
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med (2011) 13.74
Adjuvant docetaxel for node-positive breast cancer. N Engl J Med (2005) 8.00
Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet (2009) 6.92
Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol (2014) 6.28
Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol (2010) 5.01
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol (2009) 4.69
Breast cancer with synchronous metastases: trends in survival during a 14-year period. J Clin Oncol (2004) 4.51
Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol (2013) 3.67
Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol (2007) 3.35
Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res (2009) 3.31
Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol (2012) 3.07
Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol (2009) 2.88
Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol (2008) 2.85
Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. Lancet Oncol (2010) 2.74
Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res (2009) 2.51
6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. Lancet Oncol (2013) 2.39
Dendritic cell infiltration and prognosis of early stage breast cancer. Clin Cancer Res (2004) 2.34
Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing. PLoS One (2011) 2.13
Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol (2010) 2.03
Phyllodes tumor of the breast. Int J Radiat Oncol Biol Phys (2007) 2.02
Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study. Lancet Oncol (2009) 1.99
Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol (2007) 1.99
Netrin-1 expression confers a selective advantage for tumor cell survival in metastatic breast cancer. Proc Natl Acad Sci U S A (2008) 1.95
Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study. Lancet Oncol (2012) 1.91
Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. J Natl Cancer Inst (2006) 1.86
Experimental designs for small randomised clinical trials: an algorithm for choice. Orphanet J Rare Dis (2013) 1.77
AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. J Clin Oncol (2013) 1.77
Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinomas of unknown primary site. Cancer (2006) 1.75
Life-threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate-risk breast cancer. JAMA (2005) 1.68
Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer. Clin Cancer Res (2013) 1.68
Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis. Int J Cancer (2006) 1.65
Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol (2012) 1.55
Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study. Oncologist (2010) 1.52
Malnutrition is an independent factor associated with nosocomial infections. Br J Nutr (2004) 1.51
Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy. J Clin Oncol (2013) 1.50
Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat (2010) 1.47
Population pharmacokinetics and dosing recommendations for cisplatin during intraperitoneal peroperative administration: development of a limited sampling strategy for toxicity risk assessment. Clin Pharmacokinet (2009) 1.44
First epidemiological data from the French Trophoblastic Disease Reference Center. Am J Obstet Gynecol (2007) 1.44
Role of STAT3 in CD4+CD25+FOXP3+ regulatory lymphocyte generation: implications in graft-versus-host disease and antitumor immunity. J Immunol (2007) 1.41
2007 Standards, Options, and Recommendations: use of erythropoiesis-stimulating agents (ESA: epoetin alfa, epoetin beta, and darbepoetin) for the management of anemia in children with cancer. Pediatr Blood Cancer (2009) 1.39
A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Clin Cancer Res (2009) 1.37
CD4 lymphopenia as a risk factor for febrile neutropenia and early death after cytotoxic chemotherapy in adult patients with cancer. Cancer (2004) 1.35
Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. Gynecol Oncol (2012) 1.31
Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study--trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). J Clin Oncol (2003) 1.30
HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients. PLoS One (2007) 1.29
Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial. J Clin Oncol (2007) 1.27
Erythropoietin or Darbepoetin for patients with cancer--meta-analysis based on individual patient data. Cochrane Database Syst Rev (2009) 1.26
Impaired IFN-α production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression. Cancer Res (2012) 1.26
Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French Sarcoma Group (GSF/GETO). Cancer (2013) 1.25
Early detection of tumor cells by innate immune cells leads to T(reg) recruitment through CCL22 production by tumor cells. Cancer Res (2011) 1.24
Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer. Cancer Res (2011) 1.23
ICOS-ligand expression on plasmacytoid dendritic cells supports breast cancer progression by promoting the accumulation of immunosuppressive CD4+ T cells. Cancer Res (2012) 1.22
Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. J Clin Oncol (2013) 1.20
PI3 kinase inhibitors in the clinic: an update. Anticancer Res (2012) 1.19
Entry of hepatitis C virus pseudotypes into primary human hepatocytes by clathrin-dependent endocytosis. J Gen Virol (2006) 1.17
Continuous intravascular secretion of endostatin in mice from transduced hematopoietic stem cells. Mol Ther (2002) 1.17
Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study. Eur J Cancer (2013) 1.17
Unfulfilled promise of endostatin in a gene therapy-xenotransplant model of human acute lymphocytic leukemia. Mol Ther (2002) 1.16
Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer. J Clin Oncol (2004) 1.16
Impact of chemotherapy beyond the first line in patients with metastatic breast cancer. Breast Cancer Res Treat (2007) 1.16
Lymphopenia: a new independent prognostic factor for survival in patients treated with whole brain radiotherapy for brain metastases from breast carcinoma. Radiother Oncol (2005) 1.16
Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational study. Breast Cancer Res (2012) 1.16
Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial. BMC Cancer (2011) 1.14
Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma. Clin Cancer Res (2008) 1.12
Development and validation of a model that predicts early death among cancer patients participating in phase I clinical trials investigating cytotoxics. Invest New Drugs (2009) 1.12
Incidence of soft tissue sarcoma and beyond: a population-based prospective study in 3 European regions. Cancer (2012) 1.12
Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas. Eur J Cancer (2012) 1.11
Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST). Eur J Cancer (2010) 1.11
Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. J Clin Oncol (2010) 1.11
Bevacizumab and paclitaxel for breast cancer patients with central nervous system metastases: a case series. Clin Breast Cancer (2009) 1.11
Complete histologic response induced by sorafenib in advanced hepatocellular carcinoma: a case report. J Clin Oncol (2011) 1.10
Novel role for STAT3 in transcriptional regulation of NK immune cell targeting receptor MICA on cancer cells. Cancer Res (2011) 1.10
A candidate molecular signature associated with tamoxifen failure in primary breast cancer. Breast Cancer Res (2008) 1.10
Epidemiological evaluation of concordance between initial diagnosis and central pathology review in a comprehensive and prospective series of sarcoma patients in the Rhone-Alpes region. BMC Cancer (2010) 1.09
The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab. Eur J Cancer (2008) 1.08
Potential role of lymphadenectomy in advanced ovarian cancer: a combined exploratory analysis of three prospectively randomized phase III multicenter trials. J Clin Oncol (2010) 1.08
ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma. Cancer (2011) 1.07
Outcome of patients with advanced solitary fibrous tumors: the Centre Léon Bérard experience. BMC Cancer (2013) 1.07
Outcome of recurrent and metastatic small cell carcinoma of the bladder. BMC Urol (2009) 1.05